key: cord-0973802-iygc2hk5
authors: Olds, Hailey; Liu, Jesse; Luk, Kevin; Lim, Henry W.; Ozog, David; Rambhatla, Pranita V.
title: Telogen effluvium associated with COVID‐19 infection
date: 2021-01-14
journal: Dermatol Ther
DOI: 10.1111/dth.14761
sha: 9c636bcadee83ba485d5b3d3d8edcd04212b8ae4
doc_id: 973802
cord_uid: iygc2hk5

Telogen effluvium (TE) is characterized by diffuse hair shedding 2‐3 months after a stressor, and COVID‐19 infection is potentially one such stressor. Those who were infected with the virus were under immense psychosocial and physiologic stress. We retrospectively reviewed electronic medical records of 552 patients who were evaluated by a Henry Ford Health System dermatologist between February 2020 and September 2020 and had a diagnosis of COVID‐19 infection. Ten patients were identified with TE attributed to COVID‐19 infection and described their presentations as a case series. For the ten patients selected, the mean age was 48.5 years old and 90% were female. Six of the patients were Black, one Middle Eastern, and three White. On average, the hair shedding began 50 days after the first symptom of COVID‐19 infection. About 80% of these patients were treated with antibiotics, systemic corticosteroids, and/or hydroxychloroquine for their COVID‐19 infection and 70% were hospitalized. The presentations of these patients suggest that COVID‐19 infection may be a significant trigger of TE. TE caused by hydroxychloroquine, azithromycin or other medications cannot be ruled out, and the global pandemic itself is a source of psychosocial stress. Further studies will be needed to understand the long‐term prevalence and prognosis of TE associated with COVID‐19 infection.

T A B L E 1 Summary of 10 

We identified 10 patients that were diagnosed with TE ranging from 3 weeks to 3 months after diagnosis of COVID-19 infection ( 

The presentations of these patients suggest that COVID-19 infection may be a significant trigger of TE, possibly due to psychosocial or physiologic stress. Most of these patients had a severe enough infection that they required hospitalization and treatment with antibiotics, systemic corticosteroids, and/or hydroxychloroquine. In previous studies, it has been reported that those with more severe COVID-19

infections had higher levels of proinflammatory cytokines, which may correlate to a higher risk of TE given the proinflammatory state. 4, 5 In addition, the coagulation cascade becomes activated in response to COVID-19 infection, and there is decreased concentration of anticoagulant proteins due to decreased production and increased consumption. 5 There are limitations to our study. This was a single health system, retrospective study with a relatively small sample size. However,

Telogen effluvium: a review

Management of telogen effluvium during the COVID-19 emergency: psychological implications

Telogen effluvium: a review of the literature

COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs

COVID-19 cytokine storm: the interplay between inflammation and coagulation

Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak

Off-label use of topical minoxidil in alopecia: a review

Telogen effluvium: a sequela of COVID-19

Acute telogen effluvium associated with SARS-CoV-2 infection

Assessing differential impacts of COVID-19 on black communities

Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of the COVID-19 pandemic

Telogen effluvium associated with COVID-19 infection

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

https://orcid.org/0000-0002-6408-8625